Bd launches combination test for covid-19, influenza a/b and respiratory syncytial virus

Bd max™ molecular diagnostic respiratory viral panel ce marked to ivd directive franklin lakes, n.j. , june 30, 2022 /prnewswire/ -- bd (becton, dickinson and company) (nyse: bdx), a leading global medical technology company, announced that the bd max™ respiratory viral panel (rvp), a new molecular diagnostic combination test for sars-cov-2, influenza a + b and respiratory syncytial virus (rsv), has been ce marked to the ivd directive 98/79/ec.
BDX Ratings Summary
BDX Quant Ranking